Evidence map›Paper›PMID 29621982›Full record

ArticleBMC cancer2018

Using a nomogram based on preoperative serum fibrinogen levels to predict recurrence of papillary thyroid carcinoma.

Lei Jianyong, Li Zhihui, Gong Rixiang, Zhu Jingqiang

Abstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Fibrinogen and tumors.Frontiers in oncology · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Development and Validation of a Nomogram for Predicting Survival in Patients with Thyroid Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lei JianyongThyroid and Parathyroid Surgery Group of West China Hospital of Sichuan University, Chengdu, China.
Li ZhihuiThyroid and Parathyroid Surgery Group of West China Hospital of Sichuan University, Chengdu, China.
Gong RixiangThyroid and Parathyroid Surgery Group of West China Hospital of Sichuan University, Chengdu, China.
Zhu JingqiangThyroid and Parathyroid Surgery Group of West China Hospital of Sichuan University, Chengdu, China. zjqdoctor@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperfibrinogenemia is increasingly being recognized as an important risk factor related to cancer stage, development and outcomes. We evaluated whether preoperative serum fibrinogen levels predict recurrence of papillary thyroid carcinoma (PTC).

methodsWe retrospectively collected data for 1023 PTC patients who underwent surgery at our institution from Aug 2014 to Aug 2016. In total, 414 patients (from Aug 2014 to Dec 2015) were used as the training set to build the model, and 609 patients (from Jan 2016 to Aug 2016) were used as the testing set to validate the model.

resultsIn the training set, PTC cases with high serum fibrinogen levels were more likely to have multiple PTCs (P = 0.001) and to exhibit surrounding tissue or organ invasion (both P < 0.01). Moreover, PTC patients with higher serum fibrinogen levels were also more likely to have an advanced tumor stage (T, P = 0.001) and distance metastasis (P < 0.001), and these patients had a significantly higher rate of postoperative PTC recurrence (P = 0.002). All of these findings were validated in the testing set. The results of univariate and multivariate analyses indicated that hyperfibrinogenemia was a risk factor for PTC recurrence. The identified risk factors were incorporated into a nomogram and validated using the testing set (C-index = 0.811, 95% CI: 0.762-0.871).

conclusionPTC cases with hyperfibrinogenemia are more likely to have an advanced TNM stage and have a higher rate of PTC recurrence. Our nomogram could be used to objectively and accurately predict PTC recurrence in a clinical setting.

Indexed as

FibrinogenAdultAgedBiomarkersBiomarkers, TumorFemaleHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasm StagingNomogramsPreoperative PeriodPrognosisThyroid Cancer, PapillaryBiomarkersBiomarkers, TumorFibrinogenFibrinogenLymph node metastasisPapillary thyroid carcinomaRecurrence

Identifiers

PMID29621982
PMCPMC5887254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.